Announcement PDF ASX ANNOUNCEMENT 10 DECEMBER 2024 Change of Director’s Interest Notice Sydney, Australia – 10 December 2024 – Radiopharm Theranostics Limited (ASX:RAD, NASDAQ:RADX, “Radiopharm” or the “Company”), today announced that Executive Chairman, Mr Paul Hopper announced he has sold 5,000 American Depositary Shares (ADSs) (1,500,000 shares) on market as part of the NASDAQ listing. RAD has approved the sale of a small quantity of Mr Hopper’s shareholding to satisfy the recommendations of the US bankers and lawyers. The transaction was to provide liquidity on the first day of trading of the Company’s equity on Nasdaq. Mr Hopper said, “As the Founder, Executive Chairman and substantial holder in the Company, I remain committed to Radiopharm, and I am very excited about its prospects. I look forward to continuing to drive success for the Company and for its shareholders.” Authorised on behalf of the Radiopharm Theranostics Board of Directors by Executive Chairman Paul Hopper. Radiopharm Theranostics Limited Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia ABN: 57 647 877 889 Appendix 3Y Change of Director’s Interest Notice Rule 3.19A.2 Appendix 3Y Change of Director’s Interest Notice Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public. Introduced 30/9/2001. Amended 01/01/11 Name of Entity: Radiopharm Theranostics Limited (ASX: RAD) ABN: 57 647 877 889 We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act. Name of Director: Paul Hopper Date of Last Notice: 18 September 2024 Part 1 - Change of director’s relevant interests in securities In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part. Direct or Indirect Interest Direct Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest. Date of change 5 December 2024 No. of securities held prior to change Direct Indirect Total Class Shares 55,400,000 93,821,428 149,221,428 Options 27,500,000 9,017,518 36,517,518 American Depositary Shares (ADSs) / (RAD ordinary shares) Number acquired Shares Direct Indirect Total Options - + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 1 - Appendix 3Y Change of Director’s Interest Notice Number disposed Direct Indirect Total Shares 1,500,000* 1,500,000* Options - *5,000 American Depositary Shares (ADSs) US$28,000 (equivalent to AU$43,037.20) Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation No. of securities held after change Direct Indirect Total Shares 53,900,000 93,821,428 147,721,428 Options 27,500,000 9,017,518 36,517,518 On-market trade Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back Part 2 – Change of director’s interests in contracts Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part. Detail of contract N/A Nature of interest N/A Name of registered holder (if issued securities) N/A Date of change N/A No. and class of securities to which interest related prior to change N/A Note: Details are only required for a contract in relation to which the interest has changed Interest acquired N/A Interest disposed N/A Value/Consideration N/A Note: If consideration is non-cash, provide details and an estimated valuation Interest after change N/A + See chapter 19 for defined terms. Appendix 3Y Page 2 01/01/2011 Appendix 3Y Change of Director’s Interest Notice Part 3 – Closed period Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required? No If so, was prior written clearance provided to allow the trade to proceed during this period? N/A If prior written clearance was provided, on what date was this provided? N/A + See chapter 19 for defined terms. 01/01/2011 Appendix 3Y Page 3